Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial

Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study plan for a phase I/II trial investigating the combination of CIMAvax vaccine with nivolumab and pembrolizumab in treating patients with advanced non-small cell lung cancer or squamous head and neck cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:16.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as ECOG performance status and confirmed diagnosis of NSCLC or squamous cell head and neck cancer. Previously, this section had no information provided.
    Difference
    39%
    Check dated 2024-05-22T21:38:35.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:40:32.000Z thumbnail image

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.